Infliximab Treatment for Refractory Kawasaki Disease in Korean Children.
10.4070/kcj.2010.40.7.334
- Author:
Min Seob SONG
1
;
Sang Bum LEE
;
Sejung SOHN
;
Jin Hee OH
;
Kyung Lim YOON
;
Ji Whan HAN
;
Chul Ho KIM
Author Information
1. Department of Pediatrics, Paik Hospital, College of Medicine, Inje University, Busan, Korea. msped@yahoo.com
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Infliximab;
Kawasaki disease
- MeSH:
Aneurysm;
Antibodies, Monoclonal;
C-Reactive Protein;
Child;
Cholecystitis;
Coronary Vessels;
Dilatation;
Echocardiography;
Fever;
Follow-Up Studies;
Hepatitis;
Humans;
Korea;
Mucocutaneous Lymph Node Syndrome;
Retrospective Studies;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Korean Circulation Journal
2010;40(7):334-338
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: This was a multicenter study to evaluate the usefulness of the tumor necrosis factor-alpha (TNF-alpha) blocker infliximab for treatment of Korean pediatric patients with refractory Kawasaki disease (KD). SUBJECTS AND METHODS: Data from 16 patients throughout Korea who were diagnosed with refractory KD and received infliximab were collected retrospectively. RESULTS: Complete response to therapy with cessation of fever occurred in 13 of 16 patients. C-reactive protein (CRP) concentrations decreased following infliximab infusion in all 14 patients in whom it was measured before and after treatment. There were no infusion reactions or complications associated with infliximab except in 1 case with acute hepatitis occurring during treatment followed by calculous cholecystitis 4 months later. Fifteen patients had coronary artery (CA) abnormalities before infliximab therapy. Three had transient mild dilatation and 9 had CA aneurysms, with subsequent normalization in 4 patients, persistent mild dilatation in 3, persistent aneurysm in 2, and there were 3 cases (2 with CA aneurysm, 1 with mild CA dilatation) without follow-up echocardiography. CONCLUSION: The results of this study suggest that infliximab may be useful in the treatment of refractory KD, and it appears that there is no significant further progression of CA lesions developing after infliximab treatment. Multicenter trials with larger numbers of patients and long-term follow-up are necessary to assess the clinical efficacy and safety of infliximab in refractory KD.
